Back to news

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

PR Newswire•17/11/2026•08:31 ET
0

Key Highlights

  • ➤MetaVia (MTVA) completes final patient visit in extended 24-week Phase 1 Part 3A study
  • ➤DA-1726 delivered 68.1% placebo-adjusted liver-fat reduction in Part 3B interim data
  • ➤DA-1726 produced 13.5% placebo-adjusted weight loss after 16 weeks
  • ➤Full Parts 3A and 3B data expected in first quarter of 2027
  • ➤Phase 2 MetALD and ALD study targeting up to 150 patients in second half of 2027

Expert Statements

Hyung Heon Kim, President and Chief Executive Officer of MetaVia

“The encouraging preliminary safety and tolerability observations in Part 3A supported our decision to extend treatment for an additional eight weeks at the 48 mg dose, providing an opportunity to further assess the durability of treatment effects and longer-term safety of DA-1726.”

Hyung Heon Kim, President and Chief Executive Officer of MetaVia

“Simultaneously, we were finalizing the Part 3B interim data for presentation at the Precision Liver Symposium 2026 and advancing preparations for Phase 2 development. The recently reported Part 3B interim results demonstrated a statistically significant 68.1% placebo-adjusted reduction in liver fat, accompanied by 13.5% placebo-adjusted weight loss and improvements in glycemic control. These findings further strengthen our confidence in the potential of DA-1726 to address multiple aspects of liver-related cardiometabolic disease.”

Hyung Heon Kim, President and Chief Executive Officer of MetaVia

“We look forward to reporting the full data from Parts 3A and 3B in the first quarter of 2027, which we expect will provide additional insight into the safety, tolerability and metabolic effects of DA-1726. Building on these encouraging findings, we are preparing to initiate a 48-week, non-biopsy Phase 2 study in up to 150 patients with metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), targeted to begin in the second half of 2027.”

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 PR Newswire

Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in